PAP
JAZZ icon

Persistent Asset Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Persistent Asset Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-115
Closed -$2.35K – 406
2025
Q3 		$2.35K Buy
+115
New +$13.8K ﹤0.01% 229

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Persistent Asset Partners's JAZZ Position: Q1 2026 in Review

Persistent Asset Partners increased its Jazz Pharmaceuticals (JAZZ) stake by 741% in Q1 2026, buying an estimated $2.45M and bringing the position to 15,905 shares worth $3.01M. The position accounts for 1.12% of the portfolio, ranked #19.

Persistent Asset Partners first reported a position in JAZZ in Q1 2025 and has held it in 5 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Persistent Asset Partners held 15,905 shares of Jazz Pharmaceuticals worth $3.01M as of Q1 2026.
  • Persistent Asset Partners bought 14,014 Jazz Pharmaceuticals shares in Q1 2026, an estimated $2.45M.
  • Jazz Pharmaceuticals made up 1.12% of Persistent Asset Partners's portfolio in Q1 2026, its #19 holding.
  • Persistent Asset Partners first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.